Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

NCT04354727 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT04354727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04354727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Phase 1/2
Overall status
Withdrawn
Start date
December 15, 2020
Completion date
June 15, 2023
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis